MindAffect has raised new funding for its hearing diagnostics solution that uses brain-computer interface technology.

Agcurate, an agritech startup based in Arnhem, the Netherlands, has announced its acquisition of Dr. Agro, a prominent player in Azerbaijan known for its ...

Since 2023, Vitestro is running the world’s largest-scale clinical trial for autonomous blood drawing devices in collaboration with hospitals and medical centres in the Netherlands.

Utrecht-based Vitestro, a company specialised in autonomous blood drawing technology, has secured $22M (approximately €20M) funding.

Rusza BCC STARTUPS - nowa linia biznesowa Business Centre Club. Najstarsza i największa organizacja pracodawców otwiera się na młodych przedsiębiorców ...

A new website launched this month promises to help families bridge gaps between generations. Using artificial intelligence (AI), the storytelling tool from British startup TELL Ltd. allows families to ...

Revolut, one of Britain’s biggest fintech startups, has about a third of its British workforce based outside London as part of its remote-first working practice. “Revolut UK is able to access a wider ...

One reason is that disability tech startups are often considered too niche to attain business viability -- at least on the scale that venture capital demands. By definition, they are assumed to be ...

A Dutch startup has launched a retro-styled electric coupe that is around a tonne lighter than most models and has an affordable price.

We identified the most exciting, innovative, and top electric vehicle startups to watch in 2024 and beyond. From electric minivans to autonomous electric cars, these are the EV companies making waves ...

Welcome to Startups Weekly — your weekly recap of everything you can’t miss from the world of startups. Sign up here to get it in your inbox every Friday. After years of booming growth, the AI ind ...

The symposium discussed how this emerging AI space wants to change the clinical environment. But first, industry stakeholders will need to solve the puzzle of approval, panelists said.